Resonant Medical announces new CEO, VP Strategic Marketing and Chairman of the Board of Directors

MONTREAL, Canada, May 23, 2007 – Resonant Medical Inc. announced today the addition of three experienced business leaders from the fields of medical equipment and radiation oncology to senior positions of the Company’s Leadership Team.

Steven G. Arless has been appointed to the position of President and CEO. The Company’s co-founder, Fred Francis, who served as Resonant’s President and CEO since the Company’s inception, will remain as Executive Vice-President of Corporate Development.

“Resonant Medical has developed innovative ultrasound-based IGRT technologies used during both the planning and treatment of various cancers with radiation”, commented Mr. Arless. “I am excited to join this dynamic company at this stage in its growth.”

“Steve has a proven track record in medical equipment and we welcome him to the team. As a seasoned CEO, he will help the Company realize its market potential in the field of image guided radiation therapy", explained Frederic Francis.

The Company also announced that Alfred J. Lawson, Ph.D. has joined the company as Vice-President of Strategic Marketing. Mr. Lawson has an extensive clinical background and experience in the commercialization of radiation oncology technologies.

Finally, William E. Curran, a former executive at Philips Medical Systems and Philips Electronics N.A., has been elected as Chairman of the Board of Directors, replacing John C. Ford, a 30 year radiation oncology industry veteran and former top executive of Varian Medical Systems. Mr. Ford will continue to serve on the Board of Directors.

“It is a privilege to work with such a group of experienced executives”, commented Mr. Curran. “We wish to thank John for his invaluable service to the Company and look forward to his continued contribution.”
Short biographies

Mr. Arless has over 35 years experience in the development, marketing and sales of medical devices products, most recently at CryoCath as President and Chief Executive Officer, and at Smith & Nephew Inc. where he served as President. Mr. Arless serves on the Board of Directors of a number of medical devices companies and professional Medical and industrial associations, as well as the Advisory Boards of both McGill University’s Faculty of Science, and Concordia University’s John Molson School of Business.

Alfred J. Lawson, Ph.D., previously worked at Varian Medical Systems. Mr. Lawson has also served as administrative director of a number of Radiation Oncology programs in Florida and Tennessee, a faculty member of the University of Alabama School of Medicine and Comprehensive Cancer Center in Birmingham, and clinical adjunct professor of Radio-biology at the University of Tennessee Center for Health Sciences in Memphis.

William E. Curran is a former executive of Philips, a leading manufacturer of systems for diagnostic imaging, oncology treatment planning and patient monitoring as well as provider of information management and other medical products. He held a number of senior management positions in Philips’ medical business and served as CFO and CEO of Philips Electronics North America.

John C. Ford Ph.D. is a recognized expert in medical technology, radiation and medical physics, and radiation oncology. Dr. Ford is a former executive of Varian Medical Systems where he served as President of Varian International Marketing, Senior Vice President of Oncology Systems Division, and Senior Scientist.

About Resonant Medical and Restitu™
Resonant Medical Inc. is a leader in the research, development and marketing of 3D ultrasound image-guided radiotherapy products designed to improve treatment planning, verification and delivery. Recently, the company secured significant financing in order to develop and market Restitu™ add-on modules that will improve the quality of radiotherapy treatment for patients with breast, head & neck, cervix, bladder, and other soft tissue malignancies. These modules will compliment the previously released prostate module and Restitu™ platform, which are already in use in dozens of cancer clinics and university hospitals in North America.

The Restitu™ Platform accurately visualizes and corrects daily changes in tumor position, shape and size, thus ushering in a new era of 3D ultrasound (U/S) multimodality radiotherapy treatment planning and image guidance. Installed in CT-Sim rooms, Restitu U/S-Sim™ allows for better definition of planning tumor volumes with its patented IMPLICIT REGISTRATION™ technology that automatically fuses 3D U/S to CT data. With U/S-Sim, multimodality treatment planning has now been made possible and affordable for all clinics, with or without PET or MRI. Installed in treatment rooms, Restitu U/S-Guide™ allows for highly accurate patient position verification and alignment, with its proprietary MUTUAL REFERENCING™ technology that uses assisted segmentation for efficient and robust intramodality 3D U/S image-guidance.

For more information, please contact:

Luc Sirois
Chief Operation Officer
Resonant Medical
M.: 514.518-0449
T.: 514-985-2442 x 267
F.: 514.985-9662